VT
REGN icon

Vise Technologies’s Regeneron Pharmaceuticals REGN Stock Holding History

Vise Technologies’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Hold
1,402
– – 0.02% 561
2025
Q4 		$1.08M Buy
1,402
+333
+31% +$226K 0.02% 565
2025
Q3 		$601K Sell
1,069
-1,074
-50% -$607K 0.02% 588
2025
Q2 		$1.12M Buy
+2,143
New +$1.2M 0.05% 407
2024
Q4 		$560K Buy
786
+323
+70% +$271K 0.05% 393
2024
Q3 		$487K Buy
463
+235
+103% +$262K 0.06% 308
2024
Q2 		$240K Buy
228
+16
+8% +$15.5K 0.04% 365
2024
Q1 		$204K Buy
+212
New +$202K 0.04% 361
2022
Q3 		– Sell
-412
Closed -$244K – 337
2022
Q2 		$244K Buy
+412
New +$268K 0.09% 243

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vise Technologies's REGN Position: Q1 2026 in Review

Vise Technologies held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 1,402 shares worth $1.08M. The position accounts for 0.02% of the portfolio, ranked #561.

Vise Technologies first reported a position in REGN in Q2 2022 and has held it in 9 quarters since. The position peaked at $1.12M in Q2 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Vise Technologies held 1,402 shares of Regeneron Pharmaceuticals worth $1.08M as of Q1 2026.
  • Vise Technologies left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.02% of Vise Technologies's portfolio in Q1 2026, its #561 holding.
  • Vise Technologies first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 9 quarters since.
  • Vise Technologies's Regeneron Pharmaceuticals position peaked at $1.12M in Q2 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.